If you have traveled to any area in the US that is considered a “hot spot” with increasing amount of cases of COVID please alert our office before coming in for any appointment. All VCS sites will be conducting temperature checks for all patients and visitors at entrances. For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. FOR THE LATEST UP TO DATE INFORMATION, ALERTS AND CANCELLATIONS PLEASE CLICK HERE

Neelima Denduluri, MD of Virginia Cancer Specialists contributes to ASCO Guideline for Early Breast Cancer Treatment

Virginia Cancer Specialists Practice Blog

May 31, 2018
Virginia Cancer Specialists » VCS Practice News » Cancer Types » VCS Practice News » Breast Cancer » Neelima Denduluri, MD of Virginia Cancer Specialists contributes to ASCO Guideline for Early Breast Cancer Treatment

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update

Neelima Denduluri, Mariana Chavez-MacGregor, Melinda L. Telli, Andrea Eisen, Stephanie L. Graff, Michael J. Hassett, Jamie N. Holloway, Arti Hurria, Tari A. King, Gary H. Lyman, Ann H. Partridge, Mark R. Somerfield, Maureen E. Trudeau, Antonio C. Wolff, and Sharon H. Giordano


To update key recommendations of the ASCO guideline adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for breast cancer.


The Expert Panel reviewed phase III trials that evaluated adjuvant capecitabine after completion of standard preoperative anthracycline- and taxane-based combination chemotherapy by patients with early-stage breast cancer HER2-negative breast cancer with residual invasive disease at surgery; the addition of 1 year of adjuvant pertuzumab to combination chemotherapy and trastuzumab for patients with early-stage, HER2-positive breast cancer; and the use of neratinib as extended adjuvant therapy for patients after combination chemotherapy and trastuzumab-based adjuvant therapy with early-stage, HER2-positive breast cancer.

Read Full Guideline on the ASCO Website here from the Journal of Clinical Oncology.